"The controllability of µCPC and the lower risk of vitreous opacities make µCPC a very welcome alternative, which we already see as the first option after drip therapy has been exhausted. It does not obstruct any later options and offers a very friendly aftercare profile."

 MUNICH EYE

"If SLT does not provide sufficient pressure reduction and the patient is biophakic, µCPC by A.R.C. Laser is a welcome gentle treatment option for mild/moderate PCOWG."

Eye Center Hildesheim-Alfeld

"In our project country Tanzania, A.R.C.-µCPC is a good and, above all, cost-effective and easily accessible treatment option to prevent visual impairment and blindness due to advanced glaucoma in a low-income setting.

The favorable side effect profile also has the potential to make µCPC an earlier treatment option to save even more eyes from irreversible blindness."

TanZanEye Project

"In our setting with many patients with advanced glaucoma, where the options were previously only timolol or trabeculectomy, µCPC is a very welcome alternative. Our patients appreciate the quick and easy treatment, and we are very pleased with the results so far."

Norton Eye Unit, Simbabwe

My experience with mCPC has been overwhelmingly positive, both from a clinical and patient care perspective. Traditionally, managing IOP in glaucoma patients has been a challenge, often requiring a combination of medication and invasive surgeries. mCPC has offered an effective, minimally invasive alternative that has transformed how we approach glaucoma treatment.
Unlike continuous-wave cyclophotocoagulation, mCPC minimizes collateral tissue damage, reducing post-operative inflammation and discomfort for patients. This has resulted in shorter recovery times and fewer complications, which is a significant advancement in patient care.
From a treatment efficacy standpoint, I have observed substantial and sustained reductions in IOP in many of my patients who have undergone mCPC. This has been particularly beneficial for patients who were either non-responsive to medications or were unable to tolerate them due to side effects.
Another advantage is the repeatability of the procedure. In cases where the IOP begins to creep back up, mCPC can be safely repeated. This flexibility in treatment is invaluable in a progressive condition like glaucoma.
Furthermore, the patient response to mCPC has been extremely positive. Many of my patients express relief and satisfaction with the procedure, noting the ease of the treatment and the improvement in their quality of life. This patient satisfaction is, for me, one of the most rewarding aspects of using this technology.
In summary, mCPC has been a game-changer in glaucoma management. It has enhanced our ability to provide effective, patient-friendly treatment options, thereby improving the quality of life for our patients and advancing the field of ophthalmology.

Nicolae Testemitanu State University of Medicine and Pharmacy

"My patients that were followed-up for the first 12 months had an initial pressure of approx. 37 mmHg and an IOP reduction between 22.5 and 27 %. In cases where more IOP reduction is needed a retreatment can be conducted after 3 months. In almost 90 % of the cases the IOP have already been achieved the target we have set for each patient. From my experience it is very important to pay attention to the correct speed moving the probe along the bulb and nevertheless the total amount of laser energy applied."

Eye clinic Maracaibo, Venezuela

"µCPC is a good tool not only for reducing the IOP and pain. I see also the benefit to reduce the amount of eye drops in patients with primary open-angle glaucoma who have vision, ocular surface problems, feeling discomfort or in case of non-compliance in medication. In patients with refractory glaucoma, I have a 50 – 60 % rate of decrease in intraocular pressure." 

University Hospital Maracaibo, Venezuela

"So, we are using the µCPC in many patients; especially in patients where we are looking for a gentle treatment option and in traditional glaucoma patients. Also, in the case of patients with cataracts we combine the µCPC with cataract surgery. So far, we have very good results. Thanks to µCPC we can control our patients, even who have significant nerve injuries at low pressures levels without the need for invasive surgery. The handling of µCPC is easy and after a short learning curve we can give these patients a greater opportunity of preserving vision, even when there is very significant damage."

Eye Clinic Maracaibo, Venezuela

"On maximal topical therapy but just need a little more to achieve a target pressure? Think µCPC. 

Nearly approaching final stage glaucoma and looking for a gentle method of pressure reduction to improve the patient's quality of life? Think µCPC. 

A frail patient who is not suitable for a filtrating surgery? Think µCPC. 

We have had all these experiences and achieved great results!"

The Eye Clinic, Port-Louis, Maurice